Teva Branded Pharmaceutical Products R&D LLC
Clinical trials sponsored by Teva Branded Pharmaceutical Products R&D LLC, explained in plain language.
Research and development subsidiary of Teva, focusing on branded pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot aims to shield celiac patients from gluten damage Results expected Sep 2026 (estimated)
- New combo inhaler aims to ease asthma symptoms Results expected Sep 2026 (estimated)
- New combo inhaler aims to cut severe asthma Flare-Ups Results expected Oct 2026 (estimated)
- First human tests begin for experimental drug TEV-56286 Results expected Jan 2027 (estimated)
-
New shot aims to restore skin color in vitiligo patients
Disease control OngoingThis early-stage trial tests a new drug called TEV-53408 in 38 adults with vitiligo. The main goal is to see if the drug is safe when given as a shot under the skin. Researchers will also look for early signs that it might help bring back skin color. The study lasts 84 weeks, inc…
Phase 1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New shot aims to shield celiac patients from gluten damage
Disease control OngoingThis study tests an injectable drug called TEV-53408 in 50 adults with celiac disease who follow a gluten-free diet. Participants will be exposed to small amounts of gluten to see if the drug can prevent intestinal damage. The trial is placebo-controlled and lasts about 86 weeks,…
Phase 2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug shows promise for Long-Term control of IBD
Disease control OngoingThis study tests two different doses of TEV-48574 (duvakitug) given as a shot every 4 weeks to adults with moderate to severe ulcerative colitis or Crohn's disease. Participants who completed a previous 14-week study can join. The goal is to see if the drug can keep the disease u…
Phase 2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New combo inhaler aims to cut severe asthma Flare-Ups
Disease control OngoingThis Phase 3 trial tests whether a daily inhaler combining fluticasone (an anti-inflammatory steroid) and albuterol (a quick-relief bronchodilator) can prevent severe asthma attacks better than albuterol alone. About 2,772 adults with asthma who have had at least one severe attac…
Phase 3 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Promising myeloma combo trial pulled before it began
Disease control CancelledThis study aimed to test a new drug called TAK-573, given with steroids and other cancer drugs, for people with multiple myeloma that came back or didn't respond to treatment. The goal was to find a safe dose and see if it helps shrink tumors. However, the trial was withdrawn bef…
Phase 1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC